Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VOLITIONRX LTD Prospectus 2015

Jul 17, 2015

34395_prs_2015-07-17_ba7af435-9a7a-4b72-a45c-d4cc279a006d.zip

Prospectus

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

424B3 1 f424b3071615_424b3.htm PROSPECTUS SUPPLEMENT NO. 1 html PUBLIC "-//IETF//DTD HTML//EN" Prospectus Supplement No. 1

PROSPECTUS SUPPLEMENT NO. 1

Filed Pursuant to Rule 424(b)(3)

(To Prospectus Dated April 25, 2014, as amended)

Registration No. 333-195213

VOLITIONRX LIMITED

3,060,725 Shares of Common Stock

($0.001 par value)

This prospectus supplement supplements information contained in that certain prospectus dated April 25, 2014, as amended, of VolitionRx Limited (the “Company”), relating to the resale from time to time of up to 1,500,000 shares of the Company’s outstanding common stock and up to 1,560,725 shares of the Company’s common stock issuable upon the exercise of outstanding warrants, which are held by certain stockholders and warrant holders named in the prospectus under the section entitled “Selling Stockholders.” This prospectus supplement should be read in conjunction with the prospectus. We prepared this supplement based on the information supplied to us by the Selling Stockholders named in the table and we have not sought to verify such information. Since the date on which the Selling Stockholder provided this information, the Selling Stockholder may have sold, transferred or otherwise disposed of all or a portion of the shares of common stock that he, she or it beneficially owns.

The following amends and supplements the information set forth in the prospectus under the caption “Selling Stockholders” with respect to the Selling Stockholders named below and the respective shares of common stock beneficially owned by such Selling Stockholders that may be offered pursuant to the prospectus:

Name of Selling Stockholder Shares Beneficially Owned Prior to the Offering Shares to be Offered Shares Beneficially Owned After the Offering Percentage Beneficially Owned after the Offering
David R. Morgan 25,000 25,000 0 0.00%
Sean Marconi 12,500 12,500 0 0.00%
OTA, LLC (22) 25,000 25,000 0 0.00%
Gael Forterre (23) 74,850 12,500 62,350 *

*

Less than 1%.

(22)

Consists of 25,000 shares of common stock subject to warrants that are currently exercisable and being offered pursuant to this prospectus. Ira M. Leventhal, whose business address is One Manhattanville Road, Purchase, NY 10577, has voting and dispositive control over the securities held by OTA, LLC. Mr. Leventhal disclaims beneficial ownership of such securities. OTA, LLC is a broker dealer and is deemed by the SEC to be an underwriter with respect to the securities. David R. Morgan, a Selling Stockholder, assigned the warrants held in his name to OTA, LLC in May 2015.

(23)

Consists of 74,850 shares of common stock, of which 12,500 shares of common stock subject to warrants that are currently exercisable are being offered pursuant to this prospectus. Sean Marconi, a Selling Stockholder, assigned the warrants held in his name to Gael Forterre in April 2015.

The date of this prospectus supplement is July 17, 2015.

EDGAR Validation Code: 4B080E5B